Health Plan Coverage of GLP-1s – Is a Simple Weight Loss Exclusion Enough?

Short summary

A federal court in D.C. dismissed a class action challenging a health plan's denial of Zepbound for obstructive sleep apnea, ruling that the plan's weight-loss drug exclusion applied because the FDA approval linked Zepbound's OSA benefit to weight reduction. The court distinguished GLP-1 coverage for diabetes, where FDA approval is condition-specific regardless of obesity. Plan sponsors relying on simple weight-loss exclusions gain some comfort, but more lawsuits are expected as GLP-1 indications expand.

• •D.C. federal court upheld a health plan's weight-loss drug exclusion for Zepbound prescribed for obstructive sleep apnea
• •Court reasoned FDA approval ties Zepbound's OSA benefit to weight loss, keeping it within the exclusion
• •Plan sponsors get reassurance but should expect further litigation as GLP-1 indications broaden

Generated with AI, which can make mistakes.